II. CLAIM AMENDMENTS

1. (Original) Substituted pyrazoline compounds of general formula I,



I

wherein

R^1 represents an optionally at least mono-substituted phenyl group,

R^2 represents an optionally at least mono-substituted phenyl group,

R^3 represents a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or R^3 represents an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or R^3 represents an $-NR^4R^5-$ moiety,

R^4 and R^5, identical or different, represent a hydrogen atom, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system and/or bonded via a linear or branched alkylene group, an $-SO_2R^6$-moiety, or an $-NR^7R^8$-moiety,

with the provisos

that R^4 and R^5 do not both represent a hydrogen atom, and

that if one of the residues R^4 and R^5 represents a hydrogen atom or an alkyl, group, which is optionally at least mono-substituted with an alkoxy group, an alkoxyalkoxy group, a halogen atom or a phenyl group, the other one of these residues R^4 and R^5 does not represent a pyrid-2-yl group, which is optionally mono-substituted in the 5-position, a pyrid-5-yl group, which is optionally mono-substituted in the 2-position, a pyrimid-5-yl group, which is optionally mono-substituted in the 2-position, a pyridaz-3-yl group, which is optionally mono-substituted in the 6-position, a pyrazin-5-yl group, which is optionally mono-substituted in the 2-position, a thien-2-yl group, which is optionally mono-substituted in the 5 position, a thien-2-yl group, which is optionally at least mono-substituted in the 4-position, a benzyl group, which is optionally mono-

substituted in the 4-position of the ring, a phenethyl group, which is optionally mono-substituted in the 4-position of the ring, an optionally mono-, di- or tri-substituted phenyl group, a di-substituted phenyl group, wherein the two substituents together form an $-OCH_2O-$, $-OCH_2CH_2O_2-$ or $-CH_2CH_2O-$ chain, which is optionally substituted with one or more halogen atoms or one or two methyl groups, an —NH-phenyl-moiety, wherein the phenyl group may be mono-substituted in the 4-position, and

that if one of the residues R^4 and R^5 represents an alkynyl group, the other one of these residues R^4 and R^5 does not represent a phenyl group, which is optionally substituted in the 4-position, and

that if one of the residues R^4 and R^5 represents a hydrogen atom or a linear or branched, saturated or unsaturated, unsubstituted or substituted aliphatic radical, the other one of these residues R^4 and R^5 does not represent an unsubstituted or substituted thiazole group or an unsubstituted or substituted [1,3,4] thiadiazole group,

R^6 represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with a mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or bonded via a linear or branched alkylene group,

R^7 and R^8, identical or different, represent a hydrogen atom, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system and/or bonded via a linear or branched alkylene group,

optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereolsomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, or a corresponding salt thereof, or a corresponding solvate thereof.

2. (Original) Compounds according to claim 1, characterized in that R^1 represents a phenyl group, which is optionally substituted by one or more substituents independently selected from the group consisting of a linear or branched C_{1-6}-alkyl group, a linear or branched C_{1-6}-alkoxy group, a halogen atom, CH_2F, CHF_2, CF_3, CN, OH, NO_2, -(C=O)-R', SH, SR', SOR', SO_2R', NH_2, NHR', NR'R", -(C=O)-NH_2, -(C=O)-NHR' and -(C=O)-NR'R" whereby R' and R" for each substituent independently represent linear or branched C_{1-6} alkyl,

preferably R^1 represents a phenyl group, which is optionally substituted by one or more substituents selected from the group consisting of methyl, ethyl, F, Cl, Br and CF_3 more preferably R^1 represents a phenyl group, which is mono-substituted with a chlorine atom in the 4-position.

3. (Currently Amended) Compounds according to claim 1 ~~or 2~~, characterized in that R^2 represents a phenyl group, which is optionally substituted by one or more substituents independently selected from the group consisting of a linear or branched C_{1-6}-alkyl group, a linear or branched C_{1-6}-alkoxy group, a halogen atom, CH_2F, CHF_2, CF_3, CN, OH, NO_2, -(C=O)-R', SH, SR', SOR', SO_2R', NH_2, NHR', NR'R", -(C=O)-NH_2, -(C=O)-NHR' and -(C=O)-NR'R", whereby R and optionally R" for each substituent independently represent linear or branched C_{1-6} alkyl, preferably R^2 represents a phenyl group, which is optionally substituted by one or more substituents independently selected from the group consisting of methyl, ethyl, F, Cl, Br and CF_3, more preferably R^2 represents a phenyl group, which is di-substituted with two chlorine atoms in its 2- and 4-position.

4. (Currently Amended) Compounds according to ~~one or more of~~ claim~~s~~ 1~~-3~~, characterized in that R_3 represents a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8} cycloaliphatic group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or R^3 represents an optionally at least mono-substituted, 5- or 6-membered aryl or heteroaryl group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or R^3

represents an $-NR^4R^5$-moiety, preferably R^3 represents a saturated, optionally at least mono-substituted, optionally one or more nitrogen-atoms as ring member containing C_{3-8} cycloaliphatic group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or R^3 represents an $-NR^4R^5$-moiety, more preferably R^3 represents a pyrrolidinyl group, a piperidinyl group or a piperazinyl group, whereby each of these groups may be substituted with one or more C_{1-6}-alkyl groups, or R^3 represents an $-NR^4R^5$-moiety.

5. (Currently Amended) Compounds according to ~~one or more of~~ claim~~s~~ 1~~-4~~, characterized in that R^4 and R^5, identical or different, represent a hydrogen atom, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-6}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or an optionally at least mono-substituted, 5- or 6-membered aryl or heteroaryl group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system and/or bonded via a methylene ($-CH_2-$) or ethylene ($-CH_2-CH_2$)-group, an $-SO_2-R^6$-moiety, or an $-NR^7R^8$-moiety, preferably one of these residues R^4 and R^5 represents a hydrogen atom and the other one of these residues R^4 and R^5 represents a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or an optionally at least mono-substituted, 5- or 6-membered aryl or heteroaryl group, which may be condensed with an

optionally at least mono-substituted mono- or polycyclic ring system, an $-SO_2R^6$-moiety, or an $-NR^7R^8$-moiety, or R^4 and R^5, identical or different, each represent a C_{1-6} alkyl group, more preferably one of these residues R^4 and R^5 represents a hydrogen atom and the other one of these residues R^4 and R^5 represents an optionally at least mono-substituted pyrrolidinyl group, an optionally at least mono-substituted piperidinyl group, an optionally at least mono-substituted piperazinyl group, an optionally at least mono-substituted triazolyl group, an $-SO_2-R^6$-moiety, or an $-NR^7R^8$-moiety, or R^4 and R^5, identical or different, represent a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, a secbutyl group or a tert.-butyl group.

6. (Currently Amended) Compounds according to ~~one or more of~~ claim~~s~~ 1~~–5~~, characterized in that R^6 represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-6} aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8} cycloaliphatic group, which may be condensed with a mono- or polycyclic ring-system, or an optionally at least mono-substituted, 5- or 6-membered aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or bonded via a methylene $(-CH_2-)$ or ethylene $(-CH_2-CH2)$-group, preferably R^6 represents a C_{1-6}-alkyl group, a saturated, optionally at least mono-substituted cycloaliphatic group, which may be condensed with a mono- or polycyclic ring-system, or a phenyl group, which is optionally substituted with one or more C_{1-6} alkyl groups.

7. (Currently Amended) Compounds according to ~~one or more of~~ claims 1~~–6~~, characterized in that R^7 and R^8, identical or different, represent a hydrogen atom, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-6} aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8} cycloaliphatic group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or an optionally at least mono-substituted, 5- or 6 membered aryl or heteroaryl group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system and/or bonded via a methylene ($-CH_2-$) or ethylene ($-CH_2-CH_2-$) group, preferably R^7 and R^8, identical or different, represent a hydrogen atom or a C_{1-6} alkyl radical.

8. (Currently Amended) Compounds of general formula I according to ~~one or more of~~ claim~~s~~ 1~~ to 7~~



wherein

R^1 represents a phenyl ring, which is mono-substituted with a halogen atom, preferably a chlorine atom, in its 4-position,

R^2 represents a phenyl ring, which is di-substituted with two halogen atoms, preferably chlorine atoms, in its 2- and 4-position,

R^3 represents a pyrrolidinyl group, a piperidinyl group, a piperazinyl group, a homo-piperazinyl group, a morpholinyl group, or an $-NR^4R^5$-moiety,

R^4 represents a hydrogen atom or a linear or branched C_{1-6}-alkyl group,

R^5 represents a linear or branched C_{1-6} alkyl group, an SO_2-R^6-moiety, a pyrrolidinyl group, a piperidinyl group, a piperazinyl group, a homo-piperazinyl group, a morpholinyl group, a triazolyl group, whereby each of the heterocyclic rings may be substituted with one or more, identical or different, C_{1-6}-alkyl groups, and

R^6 represents a phenyl group, which is optionally substituted with one or more C_{1-6} alkyl groups, which may be identical or different,

optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, or a corresponding salt thereof, or a corresponding solvate thereof.

9. (Currently Amended) Compounds according to ~~one or more of~~ claim~~s~~ 1 ~~to 8~~ selected from the group consisting of:

N-piperidinyl-5-(4-Chloro-phenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-3-carboxamide,

5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4,5-dihydro-1H-pyrazole-3-carboxylic acid-[1,2 ,4]-triazole-4-yl-amide,

5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4,5-dihydro-1H-pyrazole-3-carboxylic acid-(4-methyl-piperazin-1-yl)-amide,

5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4,5—dihydro-1H-pyrazole-3-carboxylic acid diethylamide,

[5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4,5-dihydro-1H-pyrazole-3-yl]-piperidine-1-yl-methanone,

N-[5-(4-Chloro-phenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole-3-carbonyl]-4-methylphenylsulfonamide,

optionally in the form of a corresponding N-oxide, a corresponding salt or a corresponding solvate.

10. (Currently Amended) Process for the manufacture of substituted pyrazoline compounds of general formula I according to ~~one or more of~~ claim~~s~~ 1~~ to 9~~, characterized in that at least one benzaldehyde compound of general formula II



(II)

wherein R^1 has the meaning according to ~~one or more of~~ claims ~~1–9~~, is reacted with a pyruvate compound of general formula (III)



(III),

wherein R is a branched or unbranched C_{1-6} alkyl radical,

to yield a compound of general formula (IV)



(IV)

wherein R^1 has the meaning given above, which is optionally isolated and/or optionally purified, and which is reacted with an optionally substituted phenyl hydrazine of general formula (V)



(V)

or a corresponding salt thereof, wherein R^2 has the meaning according to ~~one or more of~~ claim~~s~~ 1~~–9~~, under inert atmosphere, to yield a compound of general formula (VI)



(VI)

wherein R^1 and R^2 have the meaning as given above, which is optionally isolated and/or optionally purified, and optionally transferred under inert atmosphere to a compound of general formula (VII) via the reaction with an activating agent



(VII)

wherein the substituents R^1 and R^2 have the meaning given above and A represents a leaving group, said compound being optionally isolated and/or optionally purified, and at least one compound of general formula (VI) is reacted with a compound of general formula R^3H, wherein R^3 represents an $-NR^4R^5$-moiety, with R^4 and R^5 having the meaning according to one or more of claims 1-9, under inert atmosphere to yield a substituted pyrazoline compound of general formula I, wherein R^3 represents an $-NR^4R^5$-moiety,

and/or at least one compound of general formula (VII) is reacted with a compound of the general formula R^3H, in which R^3 has the meaning according to ~~one or more of~~ claim~~s~~ 1~~-9~~ under inert atmosphere to yield a compound of general formula (I) according to ~~one or more of~~ claims 1~~-9~~, which is optionally isolated and/or optionally purified.

11. (Original) Medicament comprising at least one substituted pyrazoline compound of general formula I,



I

wherein

R^1 represents an optionally at least mono-substituted phenyl group,

R^2 represents an optionally at least mono-substituted phenyl group,

R^3 represents a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or R^3 represents an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or R^3 represents an $-NR^4R^5-$ moiety,

R^4 and R^5, identical or different, represent a hydrogen atom, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least monosubstituted, optionally at least one heteroatom as ring member containing

cycloaliphatic group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system and/or bonded via a linear or branched alkylene group, an $-SO_2-R^6$-moiety, or an $-NR^7R^8$-moiety, with the proviso that R^4 and R^5 do not identically represent hydrogen,

R^6 represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with a mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or bonded via a linear or branched alkylene group,

R^7 and R^8, identical or different, represent a hydrogen atom, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system and/or bonded via a linear or branched alkylene group,

optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, or a corresponding salt thereof, or a corresponding solvate thereof, and optionally one or more pharmaceutically acceptable excipients.

12. (Original) Medicament according to claim 11, characterized in that R^1 represents a phenyl group, which is optionally substituted by one or more substituents independently selected from the group consisting of a linear or branched C_{1-6}-alkyl group, a linear or branched C_{1-6}-alkoxy group, a halogen atom, CH_2F, CHF_2, CF_3, CN, OH, NO_2, -(C=O)-R', SH, SR', SOR', SO_2R', NH_2, NHR', NR'R", -(C=O)-NH_2, -(C=O)-NHR' and -(C=O)-NR'R" whereby R' and R" for each substituent independently represent linear or branched C_{1-6} alkyl, preferably R^1 represents a phenyl group, which is optionally substituted by one or more substituents selected from the group consisting of methyl, ethyl, F, Cl, Br and CF_3, more preferably R^1 represents a phenyl group, which is mono-substituted with a chlorine atom in the 4-position.

13. (Currently Amended) Medicament according to claim 11~~ or 12~~, characterized in that R^2 represents a phenyl group, which is optionally substituted by one or more substituents independently selected from the group consisting of a linear or branched C_{1-6} alkyl group, a linear or branched C_{1-6}-alkoxy group, a halogen atom, CH_2F, CHF_2, CF_3, CN, OH, NO_2, -(C=O)-R', SH, SR', SOR', SO_2R', NH_2, NHR', NR'R", -(C=O)-NH_2, -(C=O)-NHR' and -(C=O)-NR'R", whereby R' and optionally R" for each substituent independently

represent linear or branched C_{1-6} alkyl, preferably R^2 represents a phenyl group, which is optionally substituted by one or more substituents independently selected from the group consisting of methyl, ethyl, F, Cl, Br and CF_3, more preferably R^2 represents a phenyl group, which is di-substituted with two chlorine atoms in its 2- and 4-position.

14. (Currently Amended) Medicament according to ~~one or more of~~ claim~~s~~ 11~~–13~~, characterized in that R^3 represents a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8} cycloaliphatic group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or R^3 represents an optionally at least mono-substituted, 5- or 6-membered aryl or heteroaryl group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or R^3 represents an $-NR^4R^5$-moiety,

preferably R^3 represents a saturated, optionally at least mono-substituted, optionally one or more nitrogen-atoms as ring member containing C_{3-8} cycloaliphatic group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or R^3 represents an $-NR^4R^5$-moiety, more preferably R^3 represents a pyrrolidinyl group, a piperidinyl group or a piperazinyl group, whereby each of these groups may be substituted with one or more C_{16}-alkyl groups, or R^3 represents an $-NR^4R^5$-moiety.

15. (Currently Amended) Medicament according to ~~one or more of~~ claim~~s~~ 11~~–14~~, characterized in that R^4 and R^5, identical or

different, represent a hydrogen atom, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-6}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or an optionally at least mono-substituted, 5- or 6-membered aryl or heteroaryl group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system and/or bonded via a methylene ($-CH_2-$) or ethylene ($-CH_2-CH_2$)-group, an $-SO_2-R^6$-moiety, or an $-NR^7R^8$-moiety, preferably one of these residues R^4 and R^5 represents a hydrogen atom and the other one of these residues R^4 and R^5 represents a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-4}-cycloaliphatic group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or an optionally at least mono-substituted, 5- or 6-membered aryl or heteroaryl group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, an $-SO_2-R^6$-moiety, or an $-NR^7R^8$-moiety, or R^4 and R^5, identical or different, each represent a C_{1-6} alkyl group, more preferably one of these residues R^4 and R^5 represents a hydrogen atom and the other one of these residues R^4 and R^5 represents an optionally at least mono-substituted pyrrolidinyl group, an optionally at least mono-substituted piperidinyl group, an optionally at least mono-substituted piperazinyl group, an optionally at least mono-substituted triazolyl group, an $-SO_2-R^6$-moiety, or an $-NR^7R^8$-moiety, or R^4 and R^5, identical or different, represent a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, a sec-butyl group or a tert.-butyl group.

16. (Currently Amended) Medicament according to ~~one or more of~~ claim~~s~~ 11~~–15~~, characterized in that R^6 represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-6} aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8} cycloaliphatic group, which may be condensed with a mono- or polycyclic ring-system, or an optionally at least mono-substituted, 5- or 6-membered aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or bonded via a methylene ($-CH_2-$) or ethylene ($-CH_2-CH_2$)-group, preferably R^6 represents a C_{1-6}-alkyl group, a saturated, optionally at least mono-substituted cycloaliphatic group, which may be condensed with a mono- or polycyclic ring-system$_1$ or a phenyl group, which is optionally substituted with one or more C_{1-6} alkyl groups.

17. (Currently Amended) Medicament according to ~~one or more of~~ claim~~s~~ 11~~–16~~, characterized in that R^7 and R^8, identical or different, represent a hydrogen atom, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-6} aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8} cycloaliphatic group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or an optionally at least mono-substituted, 5- or 6 membered aryl or heteroaryl group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system and/or bonded via a methylene ($-CH_2-$) or ethylene ($-CH_2-CH_2$)-group, preferably R^7 and R^8, identical or different, represent a hydrogen atom or a C_{1-6} alkyl radical.

18. (Currently Amended) Medicament according to ~~one or more of~~ claim~~s~~ 11~~–17~~, characterized in that it comprises at least one compound of general formula I



I

wherein

R^2 represents a phenyl ring, which is mono-substituted with a halogen atom, preferably a chlorine atom, in its 4-position,

R^2 represents a phenyl ring, which is di-substituted with two halogen atoms, preferably chlorine atoms, in its 2- and 4-position,

R^3 represents a pyrrolidinyl group, a piperidinyl group, a piperazinyl group, a homo-piperazinyl group, a morpholinyl group, or an $-NR^4R^5$-moiety,

R^4 represents a hydrogen atom or a linear or branched C_{1-6}-alkyl group,

R^5 represents a linear or branched C_{1-6} alkyl group, an $-SO_2-R^6$-moiety, a pyrrolidinyl group, a piperidinyl group, a piperazinyl group, a homo-piperazinyl group, a morpholinyl group, a triazolyl group, whereby each of the heterocyclic

rings may be substituted with one or more, identical or different, C_{1-6}-alkyl groups, and

R^6 represents a phenyl group, which is optionally substituted with one or more C_{1-6} alkyl groups, which may be identical or different,

optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, or a corresponding salt thereof, or a corresponding solvate thereof.

19. (Currently Amended) Medicament according to ~~one or more of~~ claim~~s~~ 11 ~~to 18~~, characterized in that it comprises at least one compound selected from the group consisting of:

N-piperidinyl-5-(4-chloro-phenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-3-carboxamide,

5-(4-Chloro-phenyl)-1 -(2 ,4-dichloro-phenyl)-4, 5-dihydro-1 H-pyrazole-3-carboxylic acid-[1,2,4]-triazole-4-yl-amide,

5-(4-Chloro-phenyl)-1 -(2,4-dichloro-phenyl)-4,5-dihydro-1H-pyrazole-3-carboxylic acid-(4-methyl-piperazin-1-yl)-amide,

5-(4-Chloro-phenyl)-1 -(2,4-dichloro-phenyl)-4, 5-dihydro-1 H-pyrazole-3-carboxylic acid diethylamide,

[5-(4-Chloro-phenyl)-1 -(2,4-dichloro-phenyl)-4, 5-dihydro-1 H-pyrazole-3-yl]-piperidine-1-yl-methanone,

N-[5-(4-Chloro-phenyl)-1 -(2,4-dichloro-phenyl)-4, 5-dihydro-1 H-pyrazole-3-carbonyl]-4-methylphenylsulfonamide,

optionally in the form of a corresponding N-oxide, a corresponding salt or a corresponding solvate.

20. (Currently Amended) Medicament according to ~~one or more of~~ claim~~s~~ 11~~–19~~ for the modulation of cannabinoid-receptors, preferably cannabinoid 1 (CB_1) receptors, for the prophylaxis and/or treatment of disorders of the central nervous system, disorders of the immune system, disorders of the cardiovascular system, disorders of the endocrinous system, disorders of the respiratory system, disorders of the gastrointestinal tract or reproductive disorders.

21. (Currently Amended) Medicament according to ~~one or more of~~ claim~~s~~ 11~~–19~~ for the prophylaxis and/or treatment of food intake disorders, preferably bulimia, anorexia, cachexia, obesity, type II diabetus mellitus (non-insuline dependent diabetes mellitus), preferably obesity.

22. (Currently Amended) Medicament according to ~~one or more of~~ claim~~s~~ 11~~–19~~ for the prophylaxis and/or treatment of psychosis.

23. (Currently Amended) Medicament according to ~~one or more of~~ claim~~s~~ 11~~–19~~ for the prophylaxis and/or treatment of alcohol abuse and/or alcohol addiction, nicotine abuse and/or nicotine addiction, drug abuse and/or drug addiction and/or medicament

abuse and/or medicament addiction, preferably drug abuse and/or drug addiction.

24. (Currently Amended) Medicament according to ~~one or more of~~ claim~~s~~ 11~~–19~~ for the prophylaxis and/or treatment of one or more disorders selected from the group consisting of schizophrenia, anxiety, depression, epilepsy, neurodegeflerative disorders, cerebellar disorders, spinocerebellar disorders, cognitive disorders, cranial trauma, panic attacks, peripheric neuropathy, glaucoma, migraine, Morbus Parkinson, Morbus Huntington, Morbus Alzheimer, Raynaud's disease, tremblement disorders, compulsive disorders, senile dementia, thymic disorders, tardive dyskinesia, bipolar disorders, cancer, medicament-induced movement disorders, dystonia, endotoxemic shock, hemorragic shock, hypotension, insomnia, immunologic disorders, sclerotic plaques, vomiting, diarrhea, asthma, memory disorders, pruritus, pain, or for potentiation of the analgesic effect of narcotic and non-narcotic analgesics, or for influencing intestinal transit.

25. (Currently Amended) Use of at least one substituted pyrazoline compound according to ~~one or more of~~ claim~~s~~ 1~~–9~~ and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medicament for the modulation of cannabinoid-receptors, preferably cannabinoid 1 (CB_1) receptors, for the prophylaxis and/or treatment of disorders of the central nervous system, disorders of the immune system, disorders of the cardiovascular system, disorders of the endocrinous system, disorders of the respiratory system, disorders of the gastrointestinal tract or reproductive disorders.

26. (Currently Amended) Use of at least one substituted pyrazoline compound according to ~~one or more of~~ claim~~s~~ 1~~-9~~ and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medicament for the prophylaxis and/or treatment of food intake disorders, preferably bulimia, anorexia, cachexia, obesity, type II diabetus mellitus (non-insuline dependent diabetes mellitus), preferably obesity.

27. (Currently Amended) Use of at least one substituted pyrazoline compound according to ~~one or more of~~ claim~~s~~ 1~~-9~~ and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medicament for the prophylaxis and/or treatment of psychosis.

28. (Currently Amended) Use of at least one substituted pyrazoline compound according to ~~one or more of~~ claim~~s~~ 1~~-9~~ and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medicament for the prophylaxis and/or treatment of alcohol abuse and/or alcohol addiction, nicotine abuse and/or nicotine addiction, drug abuse and/or drug addiction and/or medicament abuse and/or medicament addiction, preferably drug abuse and/or drug addiction.

29. (Currently Amended) Use of at least one substituted pyrazoline compound according to ~~one or more of~~ claim~~s~~ 11~~-19~~ and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medicament for the prophylaxis and/or treatment of one or more disorders selected from the group consisting of schizophrenia, anxiety, depression, epilepsy,

neurodegenerative disorders, cerebellar disorders, spinocerebellar disorders, cognitive disorders, cranial trauma, panic attacks, peripheric neuropathy, glaucoma, migraine, Morbus Parkinson, Morbus Huntington, Morbus Alzheimer, Raynaud's disease, tremblement disorders, compulsive disorders, senile dementia, thymic disorders, tardive dyskinesia, bipolar disorders, cancer, medicament-induced movement disorders, dystonia, endotoxemic shock, hemorragic shock, hypotension, insomnia, immunologic disorders, sclerotic plaques, vomiting, diarrhea, asthma, memory disorders, pruritus, pain, or for potentiation of the analgesic effect of narcotic and non-narcotic analgesics, or for influencing intestinal transit.